Jeng MH - Search Results

1

Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status.

Hong H, Kao C, Jeng MH, Eble JN, Koch MO, Gardner TA, Zhang S, Li L, Pan CX, Hu Z, MacLennan GT, Cheng L. Hong H, et al. Among authors: jeng mh. Cancer. 2004 Jul 1;101(1):83-9. doi: 10.1002/cncr.20327. Cancer. 2004. PMID: 15221992 Free article.

2

Novel prostate-specific promoter derived from PSA and PSMA enhancers.

Lee SJ, Kim HS, Yu R, Lee K, Gardner TA, Jung C, Jeng MH, Yeung F, Cheng L, Kao C. Lee SJ, et al. Among authors: jeng mh. Mol Ther. 2002 Sep;6(3):415-21. doi: 10.1006/mthe.2002.0682. Mol Ther. 2002. PMID: 12231179 Free article.

3

Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer.

Li X, Zhang YP, Kim HS, Bae KH, Stantz KM, Lee SJ, Jung C, Jiménez JA, Gardner TA, Jeng MH, Kao C. Li X, et al. Among authors: jeng mh. Cancer Res. 2005 Mar 1;65(5):1941-51. doi: 10.1158/0008-5472.CAN-04-3666. Cancer Res. 2005. PMID: 15753394

4

Transcriptional targeting modalities in breast cancer gene therapy using adenovirus vectors controlled by alpha-lactalbumin promoter.

Li X, Zhang J, Gao H, Vieth E, Bae KH, Zhang YP, Lee SJ, Raikwar S, Gardner TA, Hutchins GD, VanderPutten D, Kao C, Jeng MH. Li X, et al. Among authors: jeng mh. Mol Cancer Ther. 2005 Dec;4(12):1850-9. doi: 10.1158/1535-7163.MCT-05-0167. Mol Cancer Ther. 2005. PMID: 16373700

5

Combination therapy of androgen-independent prostate cancer using a prostate restricted replicative adenovirus and a replication-defective adenovirus encoding human endostatin-angiostatin fusion gene.

Li X, Raikwar SP, Liu YH, Lee SJ, Zhang YP, Zhang S, Cheng L, Lee SD, Juliar BE, Gardner TA, Jeng MH, Kao C. Li X, et al. Among authors: jeng mh. Mol Cancer Ther. 2006 Mar;5(3):676-84. doi: 10.1158/1535-7163.MCT-05-0339. Mol Cancer Ther. 2006. PMID: 16546982

6

Fas ligand delivery by a prostate-restricted replicative adenovirus enhances safety and antitumor efficacy.

Li X, Liu YH, Zhang YP, Zhang S, Pu X, Gardner TA, Jeng MH, Kao C. Li X, et al. Among authors: jeng mh. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5463-73. doi: 10.1158/1078-0432.CCR-07-0342. Clin Cancer Res. 2007. PMID: 17875776

7

Prostate-restricted replicative adenovirus expressing human endostatin-angiostatin fusion gene exhibiting dramatic antitumor efficacy.

Li X, Liu YH, Lee SJ, Gardner TA, Jeng MH, Kao C. Li X, et al. Among authors: jeng mh. Clin Cancer Res. 2008 Jan 1;14(1):291-9. doi: 10.1158/1078-0432.CCR-07-0867. Clin Cancer Res. 2008. PMID: 18172281

8

NFATc1 with AP-3 site binding specificity mediates gene expression of prostate-specific-membrane-antigen.

Lee SJ, Lee K, Yang X, Jung C, Gardner T, Kim HS, Jeng MH, Kao C. Lee SJ, et al. Among authors: jeng mh. J Mol Biol. 2003 Jul 18;330(4):749-60. doi: 10.1016/s0022-2836(03)00640-5. J Mol Biol. 2003. PMID: 12850144

9

Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer.

Lee SJ, Zhang Y, Lee SD, Jung C, Li X, Kim HS, Bae KH, Jeng MH, Kao C, Gardner T. Lee SJ, et al. Among authors: jeng mh. Mol Ther. 2004 Dec;10(6):1051-8. doi: 10.1016/j.ymthe.2004.08.028. Mol Ther. 2004. PMID: 15564137 Free article.

10

HOXB13 induces growth suppression of prostate cancer cells as a repressor of hormone-activated androgen receptor signaling.

Jung C, Kim RS, Zhang HJ, Lee SJ, Jeng MH. Jung C, et al. Among authors: jeng mh. Cancer Res. 2004 Dec 15;64(24):9185-92. doi: 10.1158/0008-5472.CAN-04-1330. Cancer Res. 2004. PMID: 15604291

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

45 results

Search Page